<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971785</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-454-6075</org_study_id>
    <secondary_id>2021-001445-12</secondary_id>
    <nct_id>NCT04971785</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate whether the combination of semaglutide&#xD;
      (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR) causes&#xD;
      fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with&#xD;
      compensated cirrhosis due to NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve ≥ 1-Stage Improvement in Fibrosis According to the NASH Clinical Research Network (CRN) Classification Without Worsening of NASH in Participants Treated With SEMA + CILO/FIR Versus Placebo</measure>
    <time_frame>Week 72</time_frame>
    <description>Worsening of NASH is defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With NASH Resolution in Participants Treated with SEMA+CILO/FIR Versus Placebo</measure>
    <time_frame>Week 72</time_frame>
    <description>NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With NASH Resolution In Participants Treated With SEMA+CILO/FIR Versus CILO/FIR Alone</measure>
    <time_frame>Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥1-Stage Improvement in Fibrosis (According to the NASH CRN Classification) Without Worsening of NASH in Participants Treated With SEMA+CILO/FIR Versus SEMA Alone</measure>
    <time_frame>Week 72</time_frame>
    <description>Worsening of NASH is defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>SEMA + CILO/FIR FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive semaglutide (SEMA) 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and fixed-dose combination (FDC) of cilofexor and firsocostat (CILO/FIR 30 mg/20 mg) once daily for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEMA + Placebo-To-Match (PTM) CILO/FIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SEMA 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and PTM CILO/FIR administered once daily for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTM SEMA + CILO/FIR FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTM Semaglutide once weekly and CILO/FIR 30 mg/20 mg FDC administered once daily for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTM SEMA + PTM CILO/FIR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PTM Semaglutide once weekly and PTM CILO/FIR once daily for 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide (SEMA)</intervention_name>
    <description>Administered as subcutaneous (SC) injection</description>
    <arm_group_label>SEMA + CILO/FIR FDC</arm_group_label>
    <arm_group_label>SEMA + Placebo-To-Match (PTM) CILO/FIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilofexor (CILO)/Firsocostat (FIR)</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>PTM SEMA + CILO/FIR FDC</arm_group_label>
    <arm_group_label>SEMA + CILO/FIR FDC</arm_group_label>
    <other_name>GS-9674/GS-0976</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM SEMA</intervention_name>
    <description>Administered as SC injection</description>
    <arm_group_label>PTM SEMA + CILO/FIR FDC</arm_group_label>
    <arm_group_label>PTM SEMA + PTM CILO/FIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM CILO/FIR</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>PTM SEMA + PTM CILO/FIR</arm_group_label>
    <arm_group_label>SEMA + Placebo-To-Match (PTM) CILO/FIR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Liver biopsy consistent with cirrhosis (F4) due to NASH in the opinion of the central&#xD;
             reader. In participants who have never had a liver biopsy, a screening liver biopsy&#xD;
             may be performed&#xD;
&#xD;
          -  Screening laboratory parameters as determined by the study central laboratory:&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2, as calculated by&#xD;
                  the Modification of Diet in Renal Disease (MDRD) equation&#xD;
&#xD;
               -  HbA1c ≤ 10%&#xD;
&#xD;
               -  INR ≤ 1.4, unless due to therapeutic anticoagulation&#xD;
&#xD;
               -  Platelet count ≥ 125,000/uL&#xD;
&#xD;
               -  Alanine Aminotransferase (ALT) &lt; 5 x ULN&#xD;
&#xD;
               -  Serum albumin ≥ 3.5 g/dL&#xD;
&#xD;
               -  Serum Alkaline Phosphatase (ALP) ≤ 2 x ULN&#xD;
&#xD;
          -  BMI ≥ 23 kg/m^2 at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of decompensated liver disease, including ascites, hepatic&#xD;
             encephalopathy (HE), or variceal bleeding&#xD;
&#xD;
          -  Child-Pugh (CP) score &gt; 6 at screening, unless due to an alternative etiology such as&#xD;
             Gilbert's syndrome or therapeutic anticoagulation&#xD;
&#xD;
          -  Model for End-stage Liver Disease (MELD) score &gt; 12 at screening, unless due to an&#xD;
             alternative etiology such as therapeutic anticoagulation&#xD;
&#xD;
          -  Other causes of liver disease based on medical history and/or central reader review of&#xD;
             liver histology, including but not limited to: alcoholic liver disease, autoimmune&#xD;
             disorders (eg, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune&#xD;
             hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron&#xD;
             overload, or alpha-1-antitrypsin deficiency&#xD;
&#xD;
          -  Chronic HBV infection (HBsAg positive), or Chronic HCV infection (HCV antibody and HCV&#xD;
             RNA positive). Participants cured of HCV infection less than 2 years prior to the&#xD;
             screening visit are not eligible&#xD;
&#xD;
          -  History of liver transplantation&#xD;
&#xD;
          -  Current or prior history of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Men who habitually drink greater than 21 units/week of alcohol or women who habitually&#xD;
             drink greater than 14 units/week of alcohol (one unit is equivalent to 12 oz/360 mL of&#xD;
             beer, a 4 oz/120 mL glass of wine, or 1 oz/30 mL of hard liquor).&#xD;
&#xD;
               -  For individuals on vitamin E regimen ≥ 800 IU/day, or pioglitazone, dose must be&#xD;
                  stable, in the opinion of the investigator for at least 180 days prior to the&#xD;
                  historical or screening liver biopsy&#xD;
&#xD;
               -  For individuals on medications for diabetes, dose must be stable, in the opinion&#xD;
                  of the investigator, for at least 90 days prior to the historical or screening&#xD;
                  liver biopsy&#xD;
&#xD;
          -  History of type 1 diabetes&#xD;
&#xD;
          -  Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the period&#xD;
             from 90 days prior to the screening visit and for individuals with a qualifying&#xD;
             historical liver biopsy, for 90 days prior to the date of the historical liver biopsy&#xD;
&#xD;
          -  For participants who have not completed a series of an authorized COVID-19 vaccination&#xD;
             regimen prior to screening, a positive result for COVID-19 on SARS-CoV-2 RT-PCR test&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Institution For Liver Health dba Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Institution For Liver Health dba Arizona Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Diagnostic Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>2006 North Riverside Avenue, Suite A, Rialto, CA, 92377, US</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas Medical Clinic PA</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research, PLLC, 330 Wallace Road Suite 103, Nashville, TN, 37211, US</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Firsocostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

